Perioperative immunotherapy in soft tissue sarcomas

Affiliations

¹ Department of Medicine, Institut Bergonié, Bordeaux, France; Faculty of Medicine, University of Bordeaux, 33000 Bordeaux, France. Electronic address: a.italiano@bordeaux.unicancer.fr.

Comment

Antoine Italiano. Lancet. 2024.

. 2024 Nov 23;404(10467):2022-2023.

doi: 10.1016/S0140-6736(24)02252-9. Epub 2024 Nov 12.

¹ Department of Medicine, Institut Bergonié, Bordeaux, France; Faculty of Medicine, University of Bordeaux, 33000 Bordeaux, France. Electronic address: a.italiano@bordeaux.unicancer.fr.

No abstract available

Conflict of interest statement

AI declares a research grant and consulting fees from Bayer, Roche, MSD, Merck, BMS, Pharmamar, and Genentech.

Safety and efficacy of pembrolizumab, radiation therapy, and surgery versus radiation therapy and surgery for stage III soft tissue sarcoma of the extremity (SU2C-SARC032): an open-label, randomised clinical trial.
Mowery YM, Ballman KV, Hong AM, Schuetze SM, Wagner AJ, Monga V, Heise RS, Attia S, Choy E, Burgess MA, Bae S, Pryor DI, Van Tine BA, Tinoco G, Chmielowski B, Freeman C, Gronchi A, Meyer CF, Dickson MA, Hartner L, Davis LE, Powers BC, Moding EJ, Weinhold KJ, van de Rijn M, Brigman BE, Riedel RF, Kirsch DG. Mowery YM, et al. Lancet. 2024 Nov 23;404(10467):2053-2064. doi: 10.1016/S0140-6736(24)01812-9. Epub 2024 Nov 12. Lancet. 2024. PMID: 39547252 Clinical Trial.